CAMBRIDGE, Mass.–(BUSINESS WIRE)– #alzheimers–Cognito’s Spectris®, Showed Consistent Slowing of Cognitive and Functional Decline in Early Symptomatic AD in HOPE Pivotal Study
CAMBRIDGE, Mass.–(BUSINESS WIRE)– #alzheimers–Cognito’s Spectris®, Showed Consistent Slowing of Cognitive and Functional Decline in Early Symptomatic AD in HOPE Pivotal Study